Issues in Non-Clinical Statistics
|
|
- Rosamund Manning
- 6 years ago
- Views:
Transcription
1 Issues in Non-Clinical Statistics Stan Altan Chemistry, Manufacturing & Control Statistical Applications Team Department of Non-Clinical Statistics 1
2 Outline Introduction Regulatory Considerations Impacting Statistical Practices in Non-Clinical Development (Two Issues) Stability Analysis Issues and Controversies Equivalence Approach to Bioassay Potency Testing Issues in the Statistical Analysis of a Nonstandard Design (The N-1 Design) Excipient Compatibility Studies Wrap-up 2
3 Pharmaceutical Product Development: Discovery through Launch Lead Opt Compound Selection Discovery Formulation Development Safety Assessment Non-Clinical /Pre-Clinical Phase I First in humans Phase IIa Proof of biological activity in humans Clinical Research and Commercialization Phase IIb Phase III Registration NDA/MAA Submission Approval & Launch 3
4 Information Needed for Formulation Development Project Active Pharmaceutical Ingredient (API) fundamental physical and chemical properties of the drug molecule and other derived properties: pka,solubility,melting point,hygroscopicity Chemical stability through degradation studies Oral absorption potential of API evaluated based on the API aqueous solubility throughout the ph range of the GI Tract and the permeability of the compound in an in-situ rat intestinal loop or CaCo-2 model. Polymorphism, particle size and surface characteristics 4
5 Biopharmaceutics Classification System BCS Class I: High Solubility & High Permeability Solubility > 1 mg/ml; Permeability > 6 x 10-5 cm/s BCS Class II: Low Solubility & High Permeability Solubility < 1 mg/ml; Permeability > 6 x 10-5 cm/s BCS Class III: High Solubility & Low Permeability Solubility > 1 mg/ml; Permeability < 6 x 10-5 cm/s BCS Class IV: Low Solubility & Low Permeability Solubility < 1 mg/ml; Permeability < 6 x 10-5 cm/s CLASS BOUNDARIES HIGHLY SOLUBLE when the highest dose strength is soluble in < 250 ml water over a ph range of 1 to 7.5. HIGHLY PERMEABLE when the extent of absorption in humans is determined to be > 90% of an administered dose, based on massbalance or in comparison to an intravenous reference dose. RAPIDLY DISSOLVING when > 85% of the labeled amount of drug substance dissolves within 30 minutes using USP apparatus I or II in a volume of < 900 ml buffer solutions. 5
6 Stability Analysis : Issues and Controversies Introduction Objectives of a Stability Study Kinetic Models Design of Stability Studies Stability Models Fixed and Mixed effects Case Study Bayesian Approach 6
7 Introduction Stability is defined as the capacity of a drug substance or a drug product to remain within specifications established to ensure its identity, strength, quality, and purity throughout the retest period or expiration dating period 7
8 Introduction Purpose of Stability Testing To provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors (such as temperature, humidity, light, package) To establish a re-test period for the drug substance or an expiration date (shelf life) for the drug product To recommend storage conditions Control focused on lot mean 8
9 9 Kinetic Models (API) (Underlying Mechanism) Orders 0,1,2 where C 0 is the assay value at time 0 When k 1 and k 2 are small, ( 2) 0 (1) 0 0 ( 0) 1 ) ( ) ( ) ( 1 t k C t C e C t C t k C t C t k t k C C ) (t C and t k C C ) (t C ) ( ( 1)
10 Basic Design Randomly select containers/dosage units at time of manufacture, minimum of 3 batches, stored at specified conditions related to zones I,II,III,IV requirements At specified times 0,1,3,6,9,12,18,24,36,48,60 months, randomly select dosage units and perform assay on composite samples Basic Factors : Batch, Strength, Storage Condition, Time, Package Additional Factors: Position, Drug Substance Lot, Supplier, Manufacturing Site,... 10
11 Development Stability Study Description of Data Assay measurements at 0, 1, 3, 6, 9,12 months 3 Batches held at 25C/60%RH and 30C/65%RH and 40C/75%RH storage conditions, 3 package configurations Specification limits: % Label Claim (w/w) 11
12 Expiration Date Regression Model (Fixed Terms) If b i < 0, the expiration date (T ED ) at condition i is the solution to the equation (roots of a quadratic) LSL y ij A b i T A b ED i t t ij Var ( Ab T (, df ) i ED LSL = lower specification limit, t (,df) is the (1-) th quantile of the t-distribution with df degrees of freedom. e ij ) 12
13 Concentration % Label Expiration Date Intersection of specification limit with lower 1- sided 95% confidence bound on the batch mean Scatterplot of Observed Assay, True Concentration, Lower CL vs Time Variable Obs_Assay True_Conc LCLM Pred Time (Months) Shelf Life 13
14 Regulatory Model ICH Q1E (n b Batches, n c Conditions) Models 1,2,3 (Fixed Terms) 1. Fit individually by Batch and Condition (n b * n c models) 2. Fit by Batch, include all Conditions (fit n b constrained intercept models) 3. Fit all Batches and Conditions (fit 1 model, constrained batch intercepts, with/without constrained slopes) 14
15 Regulatory Models (ICH Q1E) Model Specification Type Number Form Number Fixed Fixed 1 2 3a 3b y y y y ijk ijk ijk ijk A A ij i A i A i Index i=batch, j=condition, k=time B B B B ij ij ij j T T T T ijk ijk ijk ijk ijk ijk ijk ijk Parameters Number Variance Parameters 2*n b *n c n b *n c n b *n c +n b n b n b *n c +n b 1 n c +n b 1 15
16 Issues with Regulatory Models Pooling across batches of drug Product Intercepts and Slopes at p=0.25 Unrealistic to assume batch potencies are identical at release (time or manufacture), batches are going to be different, so why test for equality? Residual error term used for pooling across Intercepts Why should this be the criterion for poolability? Multiple error terms possible if models 1,2 chosen P=0.25 ignores levels of process and analytical variability Cannot power a stability study design emphasis is on estimation of degradation rates Ignores the fact that the Chemistry is independent of batch, same API, rate constant is property of the molecule 16
17 Issues with Regulatory Models Are the regulatory guidelines reflective of current technology and statistical practice? This is the right time to question the pooling paradigm Equivalence approach not a way out Are we stuck in a Hypothesis Testing /Equivalence Testing rut? 17
18 Pooling across batches Mechanistic basis exists to forego pooling tests (constrained models) Assume a fixed common temperature-condition specific slope based on kinetic considerations Assume different batch-specific Intercepts Main requirement is to estimate the parameters and account for incipient variation in such a way that control over the lot mean is assured. 18
19 Mixed Model If one can assume that drug product batches arise from a fixed manufacturing process, then one can regard the batches as the primary independent statistical units. Statistical model needs to estimate : Process Mean at time of Manufacture Rate parameter Variance Structure Process (Lot-Lot) Analytical Variation Measurement error, Extraneous sources 19
20 Mixed Effects Model The mixed effects model provides a coherent modeling framework in a compact way consistent with the manufacturing process Acknowledges all sources of variation, simple but flexible variance structure Consistent with the basic philosophy that batch is the conditionally independent primary statistical unit (subject specific effects) A natural representation of a batch process, direct leadin to process simulations, bootstrapping, post commercialization studies Easily extended to multiple fixed factors under study Main objection small number of batches 20
21 Mixed Effects Model Models 4, 5 (Mixed Models, with 1 or 2 Random Terms) 4. Random Term in the Intercept 5. Random Terms in Intercept and Slopes Correlation not likely for API, may be for others 21
22 Mixed Effects Model Model Specification Type Number Form Number Fixed Mixed 4 y ijk ) ( 0 Index i=batch, j=condition, k=time i B j T ijk 5 yijk ( 0 i ) B j i Tijk ijk ijk Parameters Number Variance Parameters n c +1 2 n c
23 Case study: Data Listing Condition Month Ba tch B1 Ba tch B2 Ba tch B3 25C-60RH C-60RH C-60RH C-60RH C-60RH C-60RH C-65RH C-65RH C-65RH C-65RH C-65RH
24 Assay (%LC) Stability Profiles B1 B condition 25C-60RH 30C-65RH B Panel variable: Batch Time (Months) 24
25 Results from 5 Models Type Fixed Mixed Model Number Fixed Params. Rate Intercept ˆ e 25C 30C 25C 30C 25C 30C a 9 same same same b , , 0 26 ˆ 2, ˆ 2 Res DF
26 Shelf Life Estimates Model Fixed Models 1. Batch and Condition specific Intercept, Slope, Error 2. Batch specific Intercept, Slopes, Error 3a. Batch specific Intercept, Slopes, Common error across Batches 3b. Batch specific Intercept, Condition Specific Slopes, Common error across Batches Mixed Models 4. Combined across Batches, Conditions (Mixed model with a single Random Coefficient) 5. Combined across Batches, Conditions (Mixed model with two Random Coefficients) 25C/60RH 30C/65RH
27 Assay (%LC) Assay vs Time on Stability - M C-60RH 30C-65RH Time (Months) 27
28 Bayesian Approach Provides mechanism to include prior information to the statistical analysis of current data and to update model parameter estimates as new data are collected A more natural way to approach to CMC decision making in terms of a posterior predictive distribution 28
29 Hierarchical Model Random Intercept Model Y Y ijk ijk i ( m ) ~ ~ N(0, 2 ), 2 Add (prior) distribution on the unknown parameters, m, j, 2, 2 N( m i i j X j ijk X ijk ijk ) 29
30 Prior Distributions Expert opinion Process mean is likely between 99% and 101% m ~ N(100, 0.1) Lot to lot variance is likely between 0.1 and ~ (10, 2) Flat prior on the yearly degradation rates, ~ I(, ) 1 2 Analytical variance is likely between 0.1 to ~ (6, 2) 30
31 Parameter Estimates Frequentist Bayesian Parameters 95% Confidence Mean 95% Credible Estimate Interval (Median) Interval m , , , , , , (0.20) 0.11, (0.26) 0.17, 0.42 Method Expiration Date Storage Condition 25C 30C Frequentist Bayesian
32 Summary Current regulatory guidelines are being challenged in view of current technologies and scientific understanding needs continued discussion Bayesian framework is available needs further discussion in relation to reasonable priors, integrating scientific judgment 32
33 Equivalence Approach to Bioassay Potency Testing Introduction Modeling of Potency Curves Equivalence vs. Equality Issues 33
34 Definition of Bioassay WHO/NIBSC, J. Immunol. Methods (1998), 216, International consensus, Dev. Biol. Standard. (1999) vol 97: "A bioassay is defined as an analytical procedure measuring a biological activity of a test substance based on a specific, functional, biological response of a test system Finney, 3rd Edition (1978) Statistical Method in Biological Assay 34
35 Product induced response Product induced response Product induced response Examples of Assay Dose-Response Curves Assay Type A Assay Type B Assay Type C Day1 Day2 1 unit 1 unit 1 unit 1 unit 35
36 Parallelism of Dose-Response Curves The definition of relative potency requires the test sample and standard have an identical type of response within the assay. Two parallel response lines should be observed (any displacement between the curves is related to their relative activities.) Non-parallelism indicates that standard and test material are not acting similarly and any definition of potency is not valid. 36
37 Four Parameter Logistic f x, i x 1exp4 log( x ) log( 3) i i 1 3 where = ( 1, 2, 3, 4 ), 1 = asymptote as the concentration x 0 (for 4 >0), 2 = asymptote as x, 3 = concentration corresponding to response halfway between the asymptotes, 4 = slope parameter. 1 37
38 Variance Function Variability modeled as a function of mean response to capture heteroscedasticity: 2 2 i Var( y ) g f x,, i 2 2 where g f xi,, is the variance function with parameter, is a scale parameter. Correct specification is important for calculating standard errors of parameter estimates. Power of the mean is commonly used: 2 m Ey ( ) g f x i,, where m i i. Generalized least squares (GLS) method is used to estimate the parameters (Giltinan and Ruppert). i 38
39 Extend Model 1 to the comparison of multiple curves, say standard, test preparations. This is the context of potency testing. 39
40 Constrained Four-Parameter Logistic Conditions of Similarity: s1 = t1, s2 = t2, s4 = t4, lower upper parallelism asymptote asymptote and only s3, t3 vary. Let * s3 = log s3, * t3 = log t3. Under these conditions, the constrained model is given by: y i * 1exp 4 Islog xi It (log xi t ) s3 where t = * s3- * t3. i (2) 40
41 Current EQUALITY Approach for Similarity Testing of Dose-Response Curves For parallel-line assays, similarity is assessed using a statistical hypothesis test of equal slopes (test of Parallelism): Ho: S - T = 0, Ha: S - T ne 0 Test Statistic : T = Difference in slopes / Std Error(Difference) Conclude equality if T falls below a critical value. Problems with current approach 1. The greater the precision, greater sensitivity to declare even a very small difference as significant. t-test in this case penalizes a more precise assay 2. For assays with poor precision, it is hard to conclude even substantially different slopes as different. 41
42 Proposed Changes in USP Chapter <111> (Design and Analysis of Biological Assays) Focus on analysis design and validation issues moved to other chapters Preferred method for combination of independent assays is unweighted averaging Non-linear mixed effects models (4 and 5-parameter Logistic) Method of similarity testing of dose-response curves is shifted from an equality to an equivalence approach 42
43 Proposed EQUIVALENCE Approach for Similarity Testing Equivalence Limits are established that represent a measure of acceptable closeness in the slope estimates H 0 : The two slopes are not equivalent: H a : T - S ) < D L or ( T - S ) > D U The two slopes are equivalent. D L ( T - S ) D U, limits. where D L and D U are the equivalence Confidence Intervals (CI) for the difference in slopes can be used to test equivalence: If CI s fall within the equivalence limits then one concludes similarity in dose-response curves. 43
44 Challenges of the Equivalence Approach What to choose as the measure of nonparallelism slope difference, ratio of slopes 3 or 4 parameters for 4&5 logistic curves How to determine the equivalence limits Knowledge/experience for product and assay? Historical data that compare the STND to itself? Provisional capability-based equivalence limits tolerance intervals on slope differences of sample replicates? Lack of enough data during assay development Highly variable assays such as In-Vivo may not be able to satisfy a CI criterion use acceptance interval for the point estimate (rather than the CI)?
45 Bioassay Potency Testing Summary Equivalence approach replacing the traditional equality approach for similarity testing means that assay precision will have to be characterized very carefully during assay development Assay design will play a more important role, number of plates Further discussion is needed on a coherent approach to establishing equivalence criteria for dose response curve similarity testing 45
46 Excipient Compatibility Studies - N-1 Design Introduction Construction Analysis Issues 46
47 Introduction Prior to development of any dosage form of a drug candidate, fundamental physical and chemical properties of the drug molecule and other derived properties are studied. This information will provide possible approaches in formulation development and this early phase is known as Preformulation. Excipient Compatibility studies fall within this early phase and emphasis is on excipient effects on chemical and physical properties of the drug formulation (API stability in particular). 47
48 Introduction Objective Carry out a stability study on drugexcipient combinations to identify the most stable formulation. Complete (or close to complete) combinations are preferred over binary formulations. Economic incentive to formulate early. 48
49 Balanced Incomplete Block Designs Consider a BIBD, the simplest BIBD has 3 treatments with parameters t treatments = 3 k exp units/block = 2 b number of blocks = 3 r number of reps/trtmt = 2 number of blocks each pair of treatments occur = 1 Treatment Block A B C 1 x x 2 x x 3 x x BIBD defined by (t-1) = r(k-1) 1(3-1) = 2(2-1) = 2 49
50 Balanced Incomplete Blocked Factorial Designs (or N-1 Designs) Suppose instead of treatments A,B,C, we have say 3 classes of factors, say F 1, F 2, F 3, each with 2 levels, and we form factorial designs of each pair of factors, denoted Dij, ij, i,j=1,2,3, j>i, then D12 = 2x2 factorial design of factors F 1 and F 2 D13 = 2x2 factorial design of factors F 1 and F 3 D23 = 2x2 factorial design of factors F 2 and F 3 Then the N-1 design is the collection of these 3 factorial designs. The N-1 Design can be considered a factorial extension of the BIBD idea but not subject to the restrictions in the BIBD parameters. 50
51 General Construction of an N-1 Design Given F 1, F 2,,F p factors, so that each factor has say l i levels, i=1,2,,p, (l i 1) construct k factorial designs, the 1,2, i-1,i+1, k-th design denoted by D 12 I-1,I+1, k (full factorial design of all factors minus the ith factor), then the N-1 design is the collection of all such factorial designs. The total number of observations will be given by k N 1 l l2 3 l... l 1l 1... l i 1 i i k An N-1 Design has more points than the corresponding full factorial Design So why do an N-1 design? 51
52 Geometric 2 3 N-1 Design Y = 10*C Example Data + 10*A*C (0 means Absent) + N(0,16) Group A B C Y
53 2 3 N-1 Design Response = Mean + main effects + 2 way interactions Consider each factorial as a group, then an error term can come from the group differences and group interactions and replication if available. Solve normal equations for a non-orthogonal analysis 53
54 Example 2 3 N-1 Design Source DF Type I SS Mean Square SAS Output Error(MS)=14.68 A B C A*B A*C B*C Source DF Type III SS Mean Square A B C A*B A*C B*C
55 Non-geometric N-1 Design Four Factors Active + Filler + F = 4 Disintegrant + D = 2 Lubricant + L = 2 Flow Enhancer E = 1 Ignore Mixture Aspect of Design 55
56 Non-geometric Design Can it be a 4x2x2x1 Factorial Design 16 combinations? N-1 Design = 36 combinations 56
57 Analysis Issues Can the group interactions form a meaningful error term? Should replication be designed into the study? Geometric designs, the usual nonorthogonal analysis is straightforward and probably acceptable. For non-geometric N-1 designs, what does one do when a factor has only 1 level (Flow Enhancer example). Fractionate to get a main effects design from a combined N-0/N-1. 57
58 Wrap-up Many issues in non-clinical statistical applications We live in exciting times with the advent of new technologies and methods leading to a continuous source of statistical problems, especially in Non-Clinical applications Rutgers students and staff are at the forefront of solving these problems Thank you! 58
59 Acknowledgements J&J PRD Non-Clinical Statistics CM&C Statistical Applications Team Ray Buck Hans Coppenolle Oscar Go Areti Manola Yan Shen Jyh-Ming Shoung CM&C Client Groups at J&J PRD 59
From the Garrett Two-Stage Model to the Bayesian View: A Historical Survey of Stability Modeling 1954 to 2017
From the Garrett Two-Stage Model to the Bayesian View: A Historical Survey of Stability Modeling 1954 to 2017 William R. Porter, PhD Principal Scientist, PPPP-LLC@comcast.net Stan Altan, PhD Manufacturing,
More informationAN ALTERNATIVE APPROACH TO EVALUATION OF POOLABILITY FOR STABILITY STUDIES
Journal of Biopharmaceutical Statistics, 16: 1 14, 2006 Copyright Taylor & Francis, LLC ISSN: 1054-3406 print/1520-5711 online DOI: 10.1080/10543400500406421 AN ALTERNATIVE APPROACH TO EVALUATION OF POOLABILITY
More informationwhy open access publication of stability date is essential Mark Santillo Regional QA Officer SW England
why open access publication of stability date is essential Mark Santillo Regional QA Officer SW England } Standards for stability testing and data interpretation } Considerations for small molecule antimicrobials
More informationASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES
ASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES Adopted from ICH Guidelines ICH Q2A: Validation of Analytical Methods: Definitions and Terminology, 27 October 1994. ICH Q2B: Validation of Analytical
More informationEFFECT OF THE UNCERTAINTY OF THE STABILITY DATA ON THE SHELF LIFE ESTIMATION OF PHARMACEUTICAL PRODUCTS
PERIODICA POLYTECHNICA SER. CHEM. ENG. VOL. 48, NO. 1, PP. 41 52 (2004) EFFECT OF THE UNCERTAINTY OF THE STABILITY DATA ON THE SHELF LIFE ESTIMATION OF PHARMACEUTICAL PRODUCTS Kinga KOMKA and Sándor KEMÉNY
More informationDetermination of Design Space for Oral Pharmaceutical Drugs
Determination of Design Space for Oral Pharmaceutical Drugs Kalliopi Chatzizaharia and Dimitris Hatziavramidis School of Chemical Engineering National Technical University of Athens, Greece Design Space
More informationSleep data, two drugs Ch13.xls
Model Based Statistics in Biology. Part IV. The General Linear Mixed Model.. Chapter 13.3 Fixed*Random Effects (Paired t-test) ReCap. Part I (Chapters 1,2,3,4), Part II (Ch 5, 6, 7) ReCap Part III (Ch
More informationAutomated Stability Testing Delivering Rapid Product Development
Automated Stability Testing Delivering Rapid Product Development Dr Andy Brookes, AstraZeneca APS PharmSci 2-4 th September 2013 With thanks to: Pam Harrison, Helen Porter, Faye Turner, Arun Kamath The
More informationQuality by Design and Analytical Methods
Quality by Design and Analytical Methods Isranalytica 2012 Tel Aviv, Israel 25 January 2012 Christine M. V. Moore, Ph.D. Acting Director ONDQA/CDER/FDA 1 Outline Introduction to Quality by Design (QbD)
More informationDETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
CHAPTER 9 DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 9 Determination of drug release during
More informationPQRI Stability Shelf-Life Working Group Glossary Ver 1 0.doc
Term Accelerated testing Acceptance criteria: Batch Definition Studies designed to increase the rate of chemical degradation or physical change of a drug substance or drug product by using exaggerated
More informationUnified Approach For Performing An Analytical Methods Comparability Study IVT s LAB WEEK Presenter: Peter M. Saama, Ph.D. Bayer HealthCare LLC
Unified Approach For Performing An Analytical Methods Comparability Study IVT s LAB WEEK 2015 Presenter: Peter M. Saama, Ph.D. Bayer HealthCare LLC Agenda/ Content Page 1 Analytical Methods for Performing
More informationBest Linear Unbiased Prediction: an Illustration Based on, but Not Limited to, Shelf Life Estimation
Libraries Conference on Applied Statistics in Agriculture 015-7th Annual Conference Proceedings Best Linear Unbiased Prediction: an Illustration Based on, but Not Limited to, Shelf Life Estimation Maryna
More informationMeasurement error as missing data: the case of epidemiologic assays. Roderick J. Little
Measurement error as missing data: the case of epidemiologic assays Roderick J. Little Outline Discuss two related calibration topics where classical methods are deficient (A) Limit of quantification methods
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH From Basic to Translational: INDIRECT BIOASSAYS INDIRECT ASSAYS In indirect assays, the doses of the standard and test preparations are are applied
More informationASAP: Accelerated Stability Assessment Program. Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid.
ASAP: Accelerated Stability Assessment Program Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms Kenneth C. Waterman Research Fellow, Pfizer Inc A more rapid
More informationSTUDY OF THE APPLICABILTY OF CONTENT UNIFORMITY AND DISSOLUTION VARIATION TEST ON ROPINIROLE HYDROCHLORIDE TABLETS
& STUDY OF THE APPLICABILTY OF CONTENT UNIFORMITY AND DISSOLUTION VARIATION TEST ON ROPINIROLE HYDROCHLORIDE TABLETS Edina Vranić¹*, Alija Uzunović² ¹ Department of Pharmaceutical Technology, Faculty of
More information3.4. A computer ANOVA output is shown below. Fill in the blanks. You may give bounds on the P-value.
3.4. A computer ANOVA output is shown below. Fill in the blanks. You may give bounds on the P-value. One-way ANOVA Source DF SS MS F P Factor 3 36.15??? Error??? Total 19 196.04 Completed table is: One-way
More informationStat 500 Midterm 2 8 November 2007 page 0 of 4
Stat 500 Midterm 2 8 November 2007 page 0 of 4 Please put your name on the back of your answer book. Do NOT put it on the front. Thanks. DO NOT START until I tell you to. You are welcome to read this front
More informationStability of pharmaceutical preparations
Stability of pharmaceutical preparations ICH Guidelines Q1A(R2) Stability Testing of New Drug Substances and Products Q1B Stability Testing : Photostability Testing of New Drug Substances and Products
More informationUniversity of California, Berkeley
University of California, Berkeley U.C. Berkeley Division of Biostatistics Working Paper Series Year 2003 Paper 127 Rank Regression in Stability Analysis Ying Qing Chen Annpey Pong Biao Xing Division of
More informationAccelerated Stability Assessment Program (ASAP), a QbD case study
Accelerated Stability Assessment Program (ASAP), a QbD case study Applicazione del QbD nella produzione dei medicinali Università degli Studi di Milano, 6 Maggio 2016 1 Approaches for Shelf Life determination
More informationASAP concept and case studies
ASAP concept and case studies Sabine Thielges Stability Testing for Pharmaceuticals 20-21 March 2013 Background: Traditional Approaches to Stability Studies (ICH) 1. Long-term e.g. 25 C/60%RH, 30 C/75%RH
More informationDEMONSTRATING CAPABILITY TO COMPLY WITH A TEST PROCEDURE: THE CONTENT UNIFORMITY AND DISSOLUTION ACCEPTANCE LIMITS (CUDAL) APPROACH
1 DEMONSTRATING CAPABILITY TO COMPLY WITH A TEST PROCEDURE: THE CONTENT UNIFORMITY AND DISSOLUTION ACCEPTANCE LIMITS (CUDAL) APPROACH Jim Bergum September 12, 2011 Key Responses For Batch Release 2 Potency
More informationSwarthmore Honors Exam 2012: Statistics
Swarthmore Honors Exam 2012: Statistics 1 Swarthmore Honors Exam 2012: Statistics John W. Emerson, Yale University NAME: Instructions: This is a closed-book three-hour exam having six questions. You may
More informationChristin T. Choma TA Instruments, 109 Lukens Drive, New Castle, DE 19720, USA
Characterization of Drug-Excipient Compatibility Christin T. Choma TA Instruments, 19 Lukens Drive, New Castle, DE 1972, USA Development of a new pharmaceutical product is a complex and time-consuming
More informationThe Application of the Accelerated Stability Assessment Program (ASAP) to Quality by Design (QbD) for Drug Product Stability
AAPS PharmSciTech, Vol. 12, No. 3, September 2011 ( # 2011) DOI: 10.1208/s12249-011-9657-3 Review Article Theme: Quality by Design: Case Studies and Scientific Foundations Guest Editors: Robin Bogner,
More informationWritten Exam (2 hours)
M. Müller Applied Analysis of Variance and Experimental Design Summer 2015 Written Exam (2 hours) General remarks: Open book exam. Switch off your mobile phone! Do not stay too long on a part where you
More informationSTAT Final Practice Problems
STAT 48 -- Final Practice Problems.Out of 5 women who had uterine cancer, 0 claimed to have used estrogens. Out of 30 women without uterine cancer 5 claimed to have used estrogens. Exposure Outcome (Cancer)
More informationTo control the consistency and quality
Establishing Acceptance Criteria for Analytical Methods Knowing how method performance impacts out-of-specification rates may improve quality risk management and product knowledge. To control the consistency
More informationEnquiry. Demonstration of Uniformity of Dosage Units using Large Sample Sizes. Proposal for a new general chapter in the European Pharmacopoeia
Enquiry Demonstration of Uniformity of Dosage Units using Large Sample Sizes Proposal for a new general chapter in the European Pharmacopoeia In order to take advantage of increased batch control offered
More informationDesign of Engineering Experiments Chapter 5 Introduction to Factorials
Design of Engineering Experiments Chapter 5 Introduction to Factorials Text reference, Chapter 5 page 170 General principles of factorial experiments The two-factor factorial with fixed effects The ANOVA
More informationApplication of Gauge R&R Methods for Validation of Analytical Methods in the Pharmaceutical Industry
Application of Gauge R&R Methods for Validation of Analytical Methods in the Pharmaceutical Industry Richard K Burdick Elion Labs QPRC Meetings June 2016 Collaborators David LeBlond, CMC Statistical Consultant
More informationOutline Topic 21 - Two Factor ANOVA
Outline Topic 21 - Two Factor ANOVA Data Model Parameter Estimates - Fall 2013 Equal Sample Size One replicate per cell Unequal Sample size Topic 21 2 Overview Now have two factors (A and B) Suppose each
More informationVALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION
VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION Andrew J. Aubin and Tanya L. Jenkins Waters Corporation, Milford, MA, USA INTRODUCTION Benzocaine (4-Aminobenzoic
More informationWHITE PAPER ENSURING CONSISTENCY IN POLYMORPHIC DRUG SUBSTANCES AND PRODUCTS: When and How to Apply a Specification Limit
WHITE PAPER ENSURING CONSISTENCY IN POLYMORPHIC DRUG SUBSTANCES AND PRODUCTS: When and How to Apply a Specification Limit INTRODUCTION ENSURING CONSISTENCY To ensure the quality of pharmaceutical products,
More information22 Oral Solid Dosage Forms Chapter Objectives At the conclusion of this chapter the student should be able to:
22 Oral Solid Dosage Forms Chapter Objectives At the conclusion of this chapter the student should be able to: 1. Understand the basic concepts and challenges associated with the development of an oral
More informationSolution to Final Exam
Stat 660 Solution to Final Exam. (5 points) A large pharmaceutical company is interested in testing the uniformity (a continuous measurement that can be taken by a measurement instrument) of their film-coated
More informationContents. Preface to Second Edition Preface to First Edition Abbreviations PART I PRINCIPLES OF STATISTICAL THINKING AND ANALYSIS 1
Contents Preface to Second Edition Preface to First Edition Abbreviations xv xvii xix PART I PRINCIPLES OF STATISTICAL THINKING AND ANALYSIS 1 1 The Role of Statistical Methods in Modern Industry and Services
More informationStatistics 512: Solution to Homework#11. Problems 1-3 refer to the soybean sausage dataset of Problem 20.8 (ch21pr08.dat).
Statistics 512: Solution to Homework#11 Problems 1-3 refer to the soybean sausage dataset of Problem 20.8 (ch21pr08.dat). 1. Perform the two-way ANOVA without interaction for this model. Use the results
More informationExperimental Design and Data Analysis for Biologists
Experimental Design and Data Analysis for Biologists Gerry P. Quinn Monash University Michael J. Keough University of Melbourne CAMBRIDGE UNIVERSITY PRESS Contents Preface page xv I I Introduction 1 1.1
More informationwith the usual assumptions about the error term. The two values of X 1 X 2 0 1
Sample questions 1. A researcher is investigating the effects of two factors, X 1 and X 2, each at 2 levels, on a response variable Y. A balanced two-factor factorial design is used with 1 replicate. The
More informationPart 8: GLMs and Hierarchical LMs and GLMs
Part 8: GLMs and Hierarchical LMs and GLMs 1 Example: Song sparrow reproductive success Arcese et al., (1992) provide data on a sample from a population of 52 female song sparrows studied over the course
More informationHANDBOOK OF APPLICABLE MATHEMATICS
HANDBOOK OF APPLICABLE MATHEMATICS Chief Editor: Walter Ledermann Volume VI: Statistics PART A Edited by Emlyn Lloyd University of Lancaster A Wiley-Interscience Publication JOHN WILEY & SONS Chichester
More informationPreformulation & Solid State Chemistry Services
Preformulation & Solid State Chemistry Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides manufacturing, testing
More informationSARA Pharm Solutions
SARA Pharm Solutions Who we are? Sara Pharm Solutions European Innovative R&D-based Solid state pharmaceutical CRO 2 Company Background Incorporated in Bucharest, Romania Contract Research Organization
More informationChapter 4: Verification of compendial methods
Chapter 4: Verification of compendial methods Introduction In order to ensure accurate and reliable test results, the quality control laboratory (QCL) needs to use analytical methods (and accompanying
More informationGeneralizing the MCPMod methodology beyond normal, independent data
Generalizing the MCPMod methodology beyond normal, independent data José Pinheiro Joint work with Frank Bretz and Björn Bornkamp Novartis AG Trends and Innovations in Clinical Trial Statistics Conference
More informationOpportunities for Regulatory Relief via In Vitro Dissolution. James E. Polli June 10, 2015
Opportunities for Regulatory Relief via In Vitro Dissolution James E. Polli jpolli@rx.umaryland.edu June 10, 2015 Topics Current issues with in vitro dissolution IVIVC, IVIVR, and biopharmaceutic risk
More informationInferences for Regression
Inferences for Regression An Example: Body Fat and Waist Size Looking at the relationship between % body fat and waist size (in inches). Here is a scatterplot of our data set: Remembering Regression In
More informationserve the goal of analytical lmethod Its data reveals the quality, reliability and consistency of
Analytical method validation By Juree Charoenteeraboon, Ph.D Analytical method Goal consistent, reliable and accurate data Validation analytical method serve the goal of analytical lmethod Its data reveals
More informationGeneral Linear Model (Chapter 4)
General Linear Model (Chapter 4) Outcome variable is considered continuous Simple linear regression Scatterplots OLS is BLUE under basic assumptions MSE estimates residual variance testing regression coefficients
More informationPaper Equivalence Tests. Fei Wang and John Amrhein, McDougall Scientific Ltd.
Paper 11683-2016 Equivalence Tests Fei Wang and John Amrhein, McDougall Scientific Ltd. ABSTRACT Motivated by the frequent need for equivalence tests in clinical trials, this paper provides insights into
More informationEVALUATION OF NON-ACCELERATED STABILITY DATA. Kathleen Karpenter Dietrich and Daniel L. Weiner Merrell Dow Pharmaceuticals Inc. 1. Y ij. 2. Y a. + bx.
VALUATIO OF O-ACCLRATD STABILITY DATA Kathleen Karpenter Dietrich and Daniel L. Weiner Merrell Dow Pharmaceuticals Inc. Abstract A package of SAS macros has been written which allows users to evaluate
More informationDESIGNING EXPERIMENTS AND ANALYZING DATA A Model Comparison Perspective
DESIGNING EXPERIMENTS AND ANALYZING DATA A Model Comparison Perspective Second Edition Scott E. Maxwell Uniuersity of Notre Dame Harold D. Delaney Uniuersity of New Mexico J,t{,.?; LAWRENCE ERLBAUM ASSOCIATES,
More informationAdditionally, minor editorial changes have been made to update the monograph to current USP style.
Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 27 Oct 2017 Official Date 01 Nov 2017 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance In accordance
More informationFACULTY OF PHARMACY. M. Pharmacy I Semester (Suppl.) Examination, November 2015 (Common To All) Subject: Pharmaceutical Analytical Techniques
M. Pharmacy I Semester (Suppl.) Examination, November 2015 (Common To All) Subject: Pharmaceutical Analytical Techniques Code No. 6001 / S Note: Answer any Five questions. All questions carry equal marks.
More informationStatistics GIDP Ph.D. Qualifying Exam Methodology
Statistics GIDP Ph.D. Qualifying Exam Methodology January 9, 2018, 9:00am 1:00pm Instructions: Put your ID (not your name) on each sheet. Complete exactly 5 of 6 problems; turn in only those sheets you
More informationGeneralizing the MCPMod methodology beyond normal, independent data
Generalizing the MCPMod methodology beyond normal, independent data José Pinheiro Joint work with Frank Bretz and Björn Bornkamp Novartis AG ASA NJ Chapter 35 th Annual Spring Symposium June 06, 2014 Outline
More informationPART II VIII. CONCERNING CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS.
PART II VIII. CONCERNING CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS. The principle of GMP and the detailed guidelines are applicable to all operations which
More informationPhysicochemical Characterization of Acyclovir Topical Semisolid Dosage Forms Towards TCS Validation Flavian Ștefan Rădulescu, Dalia Simona Miron
Physicochemical Characterization of Acyclovir Topical Semisolid Dosage Forms Towards TCS Validation Flavian Ștefan Rădulescu, Dalia Simona Miron University of Medicine and Pharmacy Carol Davila, Bucharest,
More informationDesign of Engineering Experiments Part 5 The 2 k Factorial Design
Design of Engineering Experiments Part 5 The 2 k Factorial Design Text reference, Special case of the general factorial design; k factors, all at two levels The two levels are usually called low and high
More informationASAP implementation and use Sabine Thielges
ASAP implementation and use Sabine Thielges Science of Stability Conference, 12-14 October 2015 Introduction to ASAP principles Accelerated Stability Assessment Program Accelerated stress study (~ 1 month)
More informationContents. Part I: Fundamentals of Bayesian Inference 1
Contents Preface xiii Part I: Fundamentals of Bayesian Inference 1 1 Probability and inference 3 1.1 The three steps of Bayesian data analysis 3 1.2 General notation for statistical inference 4 1.3 Bayesian
More informationManual Accompanying The GPHF-Minilab
A Concise Quality Control Guide On Essential Drugs And Other Medicines Manual Accompanying The GPHF-Minilab Third Supplement To Volume II Thin Layer Chromatography Extension 2003 Antiretrovirals An Initiative
More information7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.
7. Stability indicating analytical method development and validation of and in capsule dosage form by HPLC. 7.1 INSTRUMENTS AND MATERIALS USED 7.1.1 INSTRUMENTS 1. Shimadzu LC-2010 CHT with liquid chromatograph
More informationDesign of preclinical combination studies
University of Manchester, UK Talk Outline 1 Preliminaries What is a drug combination? Data structures. Ray design 2 Combination index Sources of variability 3 Two drugs Analysis of data 4 Types of studies
More informationCDER Risk Assessment to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products
CDER Risk Assessment to Evaluate Potential Risks from the Use of Nanomaterials in Drug Products Celia N. Cruz, Ph.D. CDER Nanotechnology Working Group Office of Pharmaceutical Science 1 Disclaimer The
More information2 >1. That is, a parallel study design will require
Cross Over Design Cross over design is commonly used in various type of research for its unique feature of accounting for within subject variability. For studies with short length of treatment time, illness
More informationSetting Attainable and Practical Particle Size Specifications
Setting Attainable and Practical Particle Size Specifications Mark Bumiller HORIBA Scientific mark.bumiller@horiba.com Why Set Specifications? Product release (quality) Communicate grade to buyers Internal
More informationPHARMACEUTICAL BULLETINS
PHARMACEUTICAL BULLETINS TABLE OF CONTENTS BULLETIN 1 BULLETIN 2 BULLETIN 3 POLYMERS FOR PHARMACEUTICAL APPLICATIONS Introduction Product Descriptions Typical Properties of Lubrizol s Pharmaceutical Polymers
More informationPractical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D
University of Jordan Faculty of Pharmacy Practical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D USP Dissolution Method for PARACETAMOL 500 mg
More informationStats fest Analysis of variance. Single factor ANOVA. Aims. Single factor ANOVA. Data
1 Stats fest 2007 Analysis of variance murray.logan@sci.monash.edu.au Single factor ANOVA 2 Aims Description Investigate differences between population means Explanation How much of the variation in response
More informationMethods for Identifying Out-of-Trend Data in Analysis of Stability Measurements Part II: By-Time-Point and Multivariate Control Chart
Peer-Reviewed Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements Part II: By-Time-Point and Multivariate Control Chart Máté Mihalovits and Sándor Kemény T his article is a
More informationDesign of Screening Experiments with Partial Replication
Design of Screening Experiments with Partial Replication David J. Edwards Department of Statistical Sciences & Operations Research Virginia Commonwealth University Robert D. Leonard Department of Information
More informationImportance Of Accelerated Stability Study
Importance Of Accelerated Stability Study Accelerated stability testing All medicinal products decompose with time. Paradoxically, when this decomposition is being assessed the skilled formulator becomes
More informationProblems. Suppose both models are fitted to the same data. Show that SS Res, A SS Res, B
Simple Linear Regression 35 Problems 1 Consider a set of data (x i, y i ), i =1, 2,,n, and the following two regression models: y i = β 0 + β 1 x i + ε, (i =1, 2,,n), Model A y i = γ 0 + γ 1 x i + γ 2
More informationProcess Simulation, Parameter Uncertainty, and Risk
Process Simulation, Parameter Uncertainty, and Risk in QbD and ICH Q8 Design Space John J. Peterson GlaxoSmithKline Pharmaceuticals john.peterson@gsk.com Poor quality Better quality LSL USL Target LSL
More informationTwo-factor studies. STAT 525 Chapter 19 and 20. Professor Olga Vitek
Two-factor studies STAT 525 Chapter 19 and 20 Professor Olga Vitek December 2, 2010 19 Overview Now have two factors (A and B) Suppose each factor has two levels Could analyze as one factor with 4 levels
More informationSample size considerations in IM assays
Sample size considerations in IM assays Lanju Zhang Senior Principal Statistician, Nonclinical Biostatistics Midwest Biopharmaceutical Statistics Workshop May 6, 0 Outline Introduction Homogeneous population
More informationph-solubility diagrams and their usefulness in characterization of salts of poorly soluble drug substances
WHITE PAPER Dan Lundberg and Stefan Ulvenlund -Solubility diagrams and their usefulness in characterization of salts of poorly soluble drug substances For weak acids or bases, the aqueous solubility of
More informationStatistical Models with Uncertain Error Parameters (G. Cowan, arxiv: )
Statistical Models with Uncertain Error Parameters (G. Cowan, arxiv:1809.05778) Workshop on Advanced Statistics for Physics Discovery aspd.stat.unipd.it Department of Statistical Sciences, University of
More informationSMA 6304 / MIT / MIT Manufacturing Systems. Lecture 10: Data and Regression Analysis. Lecturer: Prof. Duane S. Boning
SMA 6304 / MIT 2.853 / MIT 2.854 Manufacturing Systems Lecture 10: Data and Regression Analysis Lecturer: Prof. Duane S. Boning 1 Agenda 1. Comparison of Treatments (One Variable) Analysis of Variance
More informationChapter 3: Statistical methods for estimation and testing. Key reference: Statistical methods in bioinformatics by Ewens & Grant (2001).
Chapter 3: Statistical methods for estimation and testing Key reference: Statistical methods in bioinformatics by Ewens & Grant (2001). Chapter 3: Statistical methods for estimation and testing Key reference:
More informationDesign & Analysis of Experiments 7E 2009 Montgomery
Chapter 5 1 Introduction to Factorial Design Study the effects of 2 or more factors All possible combinations of factor levels are investigated For example, if there are a levels of factor A and b levels
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE TEXT ON VALIDATION OF ANALYTICAL PROCEDURES Recommended
More informationSimple Linear Regression
Simple Linear Regression ST 430/514 Recall: A regression model describes how a dependent variable (or response) Y is affected, on average, by one or more independent variables (or factors, or covariates)
More informationChapter 7 FORMULATION AND CHARACTERIZATION OF PULSINCAP
161 Chapter 7 FORMULATION AND CHARACTERIZATION OF PULSINCAP 162 Chapter 7 FORMULATION AND CHARACTERIZATION OF PULSINCAP S.No. Name of the Sub-Title Page No. 7.1. Optimization of formulations of Pulsincap
More informationOrthogonal, Planned and Unplanned Comparisons
This is a chapter excerpt from Guilford Publications. Data Analysis for Experimental Design, by Richard Gonzalez Copyright 2008. 8 Orthogonal, Planned and Unplanned Comparisons 8.1 Introduction In this
More informationBlocks are formed by grouping EUs in what way? How are experimental units randomized to treatments?
VI. Incomplete Block Designs A. Introduction What is the purpose of block designs? Blocks are formed by grouping EUs in what way? How are experimental units randomized to treatments? 550 What if we have
More informationVALIDATION OF ANALYTICAL METHODS FOR PHARMACEUTICAL ANALYSIS
EXCERPT FROM: VALIDATION OF ANALYTICAL METHODS FOR PHARMACEUTICAL ANALYSIS BY OONA MCPOLIN This excerpt is provided as a preview to enable the reader to sample the content and style of this book. You can
More informationIndependence and Dependence in Calibration: A Discussion FDA and EMA Guidelines
ENGINEERING RESEARCH CENTER FOR STRUCTURED ORGANIC PARTICULATE SYSTEMS Independence and Dependence in Calibration: A Discussion FDA and EMA Guidelines Rodolfo J. Romañach, Ph.D. ERC-SOPS Puerto Rico Site
More informationReference: Chapter 14 of Montgomery (8e)
Reference: Chapter 14 of Montgomery (8e) 99 Maghsoodloo The Stage Nested Designs So far emphasis has been placed on factorial experiments where all factors are crossed (i.e., it is possible to study the
More informationQuality by Design in the Development of Analytical Procedures
Quality by Design in the Development of Analytical Procedures A discussion has been growing with a view to applying the Quality by Design (QbD) concept to the development of analytical procedures and promoting
More informationMultiple Linear Regression
Multiple Linear Regression ST 430/514 Recall: a regression model describes how a dependent variable (or response) Y is affected, on average, by one or more independent variables (or factors, or covariates).
More informationChapter 5 Introduction to Factorial Designs Solutions
Solutions from Montgomery, D. C. (1) Design and Analysis of Experiments, Wiley, NY Chapter 5 Introduction to Factorial Designs Solutions 5.1. The following output was obtained from a computer program that
More informationChemical Engineering: 4C3/6C3 Statistics for Engineering McMaster University: Final examination
Chemical Engineering: 4C3/6C3 Statistics for Engineering McMaster University: Final examination Duration of exam: 3 hours Instructor: Kevin Dunn 07 April 2012 dunnkg@mcmaster.ca This exam paper has 8 pages
More informationAddition of Center Points to a 2 k Designs Section 6-6 page 271
to a 2 k Designs Section 6-6 page 271 Based on the idea of replicating some of the runs in a factorial design 2 level designs assume linearity. If interaction terms are added to model some curvature results
More informationReport and Manage Post Marketing Changes to an Approved NDA, ANDA and BLA. Jane Weitzel Independent Consultant
Report and Manage Post Marketing Changes to an Approved NDA, ANDA and BLA Jane Weitzel mljweitzel@msn.com Independent Consultant IVT S Analytical Procedures & Methods Validation December 2016 San Diego
More informationChapter 14 Simple Linear Regression (A)
Chapter 14 Simple Linear Regression (A) 1. Characteristics Managerial decisions often are based on the relationship between two or more variables. can be used to develop an equation showing how the variables
More information